Quick Answer
Ultragenyx Pharmaceutical Inc. reported Operating Income Loss of -$535.00 million for the year ending 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +0.2% in Operating Income Loss from 2024 to 2025.
- This data is from Ultragenyx Pharmaceutical Inc.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Ultragenyx Pharmaceutical Inc.'s Operating Income Loss has declined by 3,246.9%.
- Historical annual values: Fiscal year 2025: -$535.00 million | Fiscal year 2024: -$536.00 million | Fiscal year 2023: -$569.00 million | Fiscal year 2022: -$648.92 million | Fiscal year 2021: -$381.74 million | Fiscal year 2020: -$330.12 million | Fiscal year 2019: -$424.17 million | Fiscal year 2018: -$371.37 million | Fiscal year 2017: -$328.94 million | Fiscal year 2016: -$248.01 million | Fiscal year 2015: -$147.74 million | Fiscal year 2014: -$56.78 million | Fiscal year 2013: -$32.28 million | Fiscal year 2012: -$15.99 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: